Daniel Thorek
Treatment of advanced, metastatic prostate cancer, although greatly improved with new treatments, still represents an unmet medical need. Prostate cancer expresses a molecule called hK2 (human Kallikrein 2), an enzyme...Read More
Adam Feldman
Dr. Feldman earned a BA degree in the Biological Basis of Behavior from the University of Pennsylvania, an MA degree from Boston University School of Medicine, an MD degree from...Read More
Nicole Simone
IGF (Insulin-like Growth Factor) receptor is dysregulated during prostate cancer progression. Dr. Simone and colleagues have demonstrated that caloric restriction decreases tumor growth and metastases in animal models of prostate...Read More
Matthew Schiewer
Deficiencies in the repair of DNA are a hallmark of cancer. A molecule, named PARP, is involved in DNA damage repair. The inhibition of PARP with specific medications is a...Read More
Eleni Efstathiou
Dr. Efsathiou earned both MD and PhD degrees at the University of Athens and is currently a medical oncology fellow at MD Anderson Cancer Center. New experimental medications that shut...Read More
Jennifer Rider
Low vitamin D levels in blood have been shown in numerous population-based studies to correlate with prostate cancer mortality. Also, several genetic alterations in the vitamin-D pathway-related genes have been...Read More
Scott M. Dehm
Dr. Dehm completed a BS and PhD in Biochemistry at the University of Saskatchewan and has been a Postdoctoral Fellow working with Don Tindall at the Mayo Clinic. Dr. Tindall...Read More
Atish Dipankar Choudhury
Dr. Choudhury earned a BA in Chemistry from Johns Hopkins University and both an MD and PhD from Columbia University. He completed his residency in Internal Medicine at the Brigham...Read More
